Cylembio's Bold Bet: Why IO Biotech is Pushing for Cancer Vaccine Approval Despite Phase III Setback

In the relentless battle against cancer, every scientific breakthrough, every clinical trial, and every regulatory decision holds immense weight. Recently, the world of oncology witnessed a development that is both perplexing and profoundly hopeful: IO Biotech, a company dedicated to developing innovative treatments